Pre-made Infliximab benchmark antibody ( Whole mAb, anti-TNFA/TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-274
Pre-Made Infliximab biosimilar, Whole mAb, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Infliximab biosimilar, Whole mAb, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||5vh3:HL:AB/5vh4:HL:AB/4g3y:HL/6ugs:HL:AB/6ugv:HL:AB/6ugt:HL:AB/6ugu:HL:AB|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Centocor;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;National Jewish Medical and Research Center;Xian-Janssen|
|Conditions Approved||Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Mucocutaneous lymph node syndrome;Plaque psoriasis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis|
|Conditions Discontinued||Berylliosis;Hepatitis C;Pyoderma|